PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Optibrium to Preview New In Silico Drug Discovery Platform at Molecular Med Tri-Conference 2011 - Optibrium™, a provider of software solutions for drug discovery, will be providing a sneak preview of the next generation of StarDrop™ at the Molecular Medicine Tri-Conference in San Francisco, CA, 23-25 February
Optibrium to Preview New In Silico Drug Discovery Platform at Molecular Med Tri-Conference 2011

 

NewswireToday - /newswire/ - Cambridge, United Kingdom, 2011/02/03 - Optibrium™, a provider of software solutions for drug discovery, will be providing a sneak preview of the next generation of StarDrop™ at the Molecular Medicine Tri-Conference in San Francisco, CA, 23-25 February.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The exclusive preview of this ground-breaking platform will be available on booth #501, at San Francisco’s Moscone North Convention Centre prior to its official launch at the American Chemical Society (ACS) National Exposition, 27-31 March, 2011, Anaheim, CA. StarDrop 5 includes new features focusing on compound idea generation, enhanced visualizations and mathematical data transformations.

Quickly identifying the best potential drug molecules is a major challenge; the right balance of multiple, often conflicting, property requirements must be achieved, while the uncertainty in the available data makes effective decision-making difficult. Good compounds are often thrown out in error, or missed by not searching widely enough, meaning wasted productivity, higher costs and reduced opportunity to discover new drugs.

StarDrop is a revolutionary software platform that supports pharmaceutical and biotech companies to guide their decisions while designing and prioritising molecules for progression in drug discovery. It integrates all of the available data and explicitly takes into account the underlying uncertainty to provide scientists with intuitive analyses on which to make rational decisions. It has an advantage over traditional decision support and modelling platforms, as it quickly targets compounds in the regions of chemical space that are most likely to yield successful results. Its interactive, user friendly environment brings together a comprehensive range of drug design features including ADME QSAR models, P450 metabolism models and automatic predictive model building, along with StarDrop’s unique probabilistic scoring, chemical space and Glowing Molecule™ visualizations, to improve the efficiency and productivity of the drug discovery process.

StarDrop 5, scheduled for release at ACS 2011, is a major upgrade bringing many significant enhancements and new features to further expand its capabilities. An innovative new module stimulates the search for high quality drugs by generating new chemistry ideas, prioritised against the user’s property profile requirements. This expands the chemistry around an initial compound, based on medicinal chemistry transformation rules derived from the literature or in-house chemistry expertise, to generate chemically relevant compounds and fuel a rigorous search for strategies to improve properties. In addition, extended data visualisation capabilities allow automatic generation of a wide range of interactive histograms, graphs, radar plots and chemical spaces. Combined with new functionality for performing mathematical calculations, StarDrop will help users to manipulate and explore their data without leaving the integrated StarDrop environment.

“We are extremely excited to preview StarDrop 5 during Mol Med Tri-Con 2011”, commented Ed Champness, CSO at Optibrium. “In addition to the previous generations’ features, which have been very well received by our rapidly expanding customer base, version 5 is equipped with powerful new data analysis tools and a revolutionary new capability to push drug discovery further and enable scientists to guide decisions in an intuitive way.”

The only exclusive preview of StarDrop 5, prior to the official release date, will be at the Molecular Medicine Tri-Conference in San Francisco, CA, 23-25 February, 2011 on booth #501. To learn more about StarDrop 5 please Email info[.]optibrium.com or call +44 1223 815 900.

About Optibrium Ltd
Optibrium (optibrium.com) is dedicated to providing software to guide decisions involving complex, uncertain data in an intuitive way. Optibrium’s primary product, StarDrop, is focused on the drug discovery industry, helping scientists to guide decisions in the design and selection of high quality drug candidates. Optibrium was founded in 2009 as a spin-out of BioFocus DPI (formerly Inpharmatica). The founding group was responsible for the development of StarDrop from 2003 and, prior to this, research and development of related technologies since 1994. Based in Cambridge, UK, Optibrium has a global customer base ranging from top-ten pharmaceutical companies to small biotechs and academic groups.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Optibrium to Preview New In Silico Drug Discovery Platform at Molecular Med Tri-Conference 2011

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Scottpr.com 
+44 1477 539539
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Frost & Sullivan Recognizes Ventec Life Systems for New Product Innovation - Game-changing, Modular Respiratory System, VOCSN
BD Expands Genomics Portfolio with New Single Cell Platform for RNA Expression Analysis
GE Healthcare Advances the Delivery of Cell Therapies with New Thawing Technology
Ansell Limited Announces the Closing of the Sale of its Sexual Wellness Business
PQ Bypass Earns Frost & Sullivan’s European Technology Innovation Award for its Proprietary DETOUR System for Percutaneous Bypass
Curaçao EMS Uses ZOLL Autopulse to Save Tourist in Sudden Cardiac Arrest
ZOLL to Showcase Expanded Portfolio of AEDs at Caravan Salon 2017
MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®
MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test
Datalogic Announces New Healthcare Memor X3 HC Mobile Computer
Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroAD™ Therapy System
SelectMDx to be Distributed Across Middle East by IPS Genomix
GE Healthcare Partners with Oritain to Introduce Independent Test to Confirm Country of Origin of Fetal Bovine Serum
Saebo, Inc. Awarded Patent for Low-Profile Stroke Recovery Glove

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)